Valproate, Hyperandrogenism, and Polycystic Ovaries
Arch Neurol 57:1064-1068, Isojarvi,J.I.T. & Tapanainen,J.S., 2000
Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for Epilepsy
NEJM 329:1383-1388, Isojarvi,J.I.T.,et al, 1993
Monitoring of Serum Amylase Levels During Valproic Acid Therapy
Ann Neurol 11:217-218, Bale,J.F.,et al, 1982
Pancreatitis Associated with Valproic Acid Therapy for Epilepsy
Ann Neurol 7:92, Coulter,D.S.,et al, 1980
Acute Hepatic Failure Associated with the Use of Sodium Valproate
NEJM 300:962-966, Suchy,F.J.,et al, 1979
Valproic Acid, Review of a New Antiepileptic Drug
Arch Neurol 36:393-398, Bruni,J.,et al, 1979
Effect of Valproic Acid on Hepatic Function
Neurol 28:961-964, Willmore,L.J.,et al, 1978
Risk Factors of Hyperammonemia in Patients with Epilepsy Under Valproic Acid Therapy
Medicine 93:e66, Tseng, Y.L.,et al, 2014
Chitosan May Decrease Serum Valproate and Increase Risk of Seizure Reappearance
BMJ 339:a2163, Striano,P.,et al, 2009
Valproate-Induced Hyperammonemic Encephalopathy in the Presence of Topiramate
Neurol 54:230-232, Hamer,H.M.,et al, 2000
Clumsiness, Confusion, Coma, and Valproate
Lancet 353:1408, Ellaway,C.J.,et al, 1999
Antiepileptic Drugs
NEJM 334:168-175, Brodie,M.J.&Dichter,M.A., 1996
Obesity and Endocrine Disorders in Women Taking Valproate for Epilepsy
Ann Neurol 39:579-584, 5591996., Isojarvi,J.I.T.,et al, 1996
Valproic Acid-Induced Hyperammonemic Encephalopathy:MR Appearance
AJNR 15:1779-1781, Baganz,M.D.&Dross,P.E., 1994
Comparison of Sprinkle Versus Syrup Formulations of Valproate for Bioavailability, Tolerance, and Preference
J Pediatr 120:634-638, Cloyd,J.C.,et al, 1992
Effect of Food on the Serum Concentration Profile of Enteric-Coated Valproic Acid
Neurol 38:1319-1322, Fischer,J.H.,et al, 1988
Breakthrough Seizure Following Substitution of Depakene Capsules with a Generic Product
Neurol 37:1885, MacDonald,J.T., 1987
Safe Readministration of Valproate after an Episode of Hepatotoxicity
Ann Neurol 13:688, Ramsay,R.E., 1983
Plasma Concentrations of Sodium Valproate:Their Clinical Value
Ann Neurol 14:38-42, Turnbull,D.M.,et al, 1983
Phenytoin-valproate Interaction:Importance of Saliva Monitoring in Epilepsy
BMJ 284:13-16, Knott,C.,et al, 1982
Sodium Valproate-induced Hyperammonemia Without Clinical Hepatic Dysfunction
Neurol 32:206-208, Zaret,B.S.,et al, 1982
Asymptomatic Hyperammonemia in Patients Receiving Valproic Acid
Arch Neurol 39:591-592, Murphy,J.V.,et al, 1982
Valproic Acid & Secondary Hyperammonemia
Neurol 31:1173-1174, Rawat,S.,et al, 1981
Valproic Acid
NEJM 302:661-666, Brown,T.R., 1980
Protein Binding of Valproic Acid in Uremic Patient
Neurol 30:557-559, Bruni,J.,et al, 1980
Valproic Acid & Ethosuximide Interaction
Ann Neurol 7:583-584, Mattson,R.H.,et al, 1980
Acute Intoxication with Sodium Valproate
Ann Neurol 6:552-553, Chadwick,D.W.,et al, 1979
Valproic Acid in Epilepsy:Clinical & Pharmacological Effects
Ann Neurol 3:20, Mattson,R.H.,et al, 1978
Sodium Valproate in the Treatment of Intractable Seizure Disorders:A Clinical & Electroencephalographic Study
Neurol 28:152, Adams,D.,et al, 1978
Valproic Acid:Interaction with Other Anticonvulsant Drugs
Neurol 28:892-896, Wilder,B.J.,et al, 1978